Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Clinician holding piggy bank | Image Credit: Dee Karen - stock.adobe.com
Oncology Biosimilars Offer Potential Relief From Financial Burden of Cancer Care

June 2nd 2025

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

March 4th 2025

FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
First Insulin Aspart Biosimilar Receives FDA Approval

February 20th 2025

Osteoporosis. | Image Credit: Nisit - stock.adobe.com
Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

February 18th 2025

Insulin. | Image Credit: Sherry Young- stock.adobe.com
Biosimilar Insulin Linked to Lower Prices in Europe

February 12th 2025

Continuing Medical Education
View All
June 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 30th 2025

New and Approved: FDA’s 2024 Drug Lineup

1.5 Credits / General Pharmacy
June 30th 2025

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy
June 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Standardization of Biopsy Testing and Interpreting Data
May 10th 2017

Standardization of Biopsy Testing and Interpreting Data

Genomic Testing for Trial Participation and Access
May 10th 2017

Genomic Testing for Trial Participation and Access

Engaging Patients in Oncology Trials Is a Team Effort
May 10th 2017

Engaging Patients in Oncology Trials Is a Team Effort

What Will Patients Gain From the TAPUR Study?
May 10th 2017

What Will Patients Gain From the TAPUR Study?

Drug Price Arguments Have No Easy Answer
May 10th 2017

Drug Price Arguments Have No Easy Answer

Empowering Stakeholders with Innovative Trial Designs
May 10th 2017

Empowering Stakeholders with Innovative Trial Designs

Center of Excellence: Streamlining Drug Approvals
May 10th 2017

Center of Excellence: Streamlining Drug Approvals

FDA Center of Excellence and the Drug Approval Process
May 10th 2017

FDA Center of Excellence and the Drug Approval Process

Drug Price Negotiation by CMS
May 10th 2017

Drug Price Negotiation by CMS

Improving the Drug Approval Process to Reduce Drug Costs
May 10th 2017

Improving the Drug Approval Process to Reduce Drug Costs

Off-Label Communications to Inform Formulary Management
May 10th 2017

Off-Label Communications to Inform Formulary Management

Considerations With Off-Label Communication
May 10th 2017

Considerations With Off-Label Communication

Evidence From Drug Manufacturers and Patient Access
May 10th 2017

Evidence From Drug Manufacturers and Patient Access

Off-Label Communications: What It Means for Stakeholders
May 10th 2017

Off-Label Communications: What It Means for Stakeholders

Site Logo
February 27th 2017

What We're Reading: Single-Payer Plan in Calif.; New Mexico Biosimilar Bill; and Shared Decision Making

AJMC Staff
Site Logo
October 10th 2016

Biosimilars and Interchangeability: Evolving Understanding and Regulations

Laura Joszt, MA
The FDA has already approved 4 biosimilars in the United States, but there remains a lot of uncertainty surrounding some of the legislation and regulation.
Site Logo
October 7th 2016

5 Key Takeaways From AMCP Nexus 2016

Laura Joszt, MA
Specialty pharmacy pipelines, healthy behaviors, and regulation took the stage at the Academy of Managed Care Pharmacy (AMCP)’s 2016 Nexus conference, which was held October 3-6 in National Harbor, Maryland.
Site Logo
September 28th 2016

Participating Faculty

Site Logo
September 23rd 2016

UnitedHealth's 2017 Formulary to Support Generic and Biosimilar Drugs

Surabhi Dangi-Garimella, PhD
UnitedHealth has posted a presentation on its website that provides an update to its pharmacy benefits and prescription drug lists for 2017.
Site Logo
August 8th 2016

PBMs Create a Path for Me-Too Drugs, Biosimilars on Their Oncology Formulary

Surabhi Dangi-Garimella, PhD
Pharmacy benefit managers (PBMs) and large employer organizations are taking measures to save healthcare costs in 2017, and for PBMs, formulary exclusions is a fool-proof tactic.
Site Logo
July 6th 2016

What We're Reading: VA Healthcare Operations Still Require "Urgent Reform"

AJMC Staff
What we're reading, July 6, 2016: the Department of Veterans Affairs has made progress, but still has a long way to go; court upholds 6-month delay for biosimilars; and Apple promotes organ donation with iPhone app.
Site Logo
June 24th 2016

What We're Reading: How Brexit Could Impact Drug Regulation

AJMC Staff
What we're reading, June 24, 2016: Britain's decision to leave the European Union will impact drug regulation; Supreme Court decision derails California proposal to allow illegal immigrants to buy health insurance; and lawmakers look to reduce exclusivity period for biologics.
Site Logo
June 21st 2016

Industry Insight on the Challenges With Developing and Adopting Biosimilars

Surabhi Dangi-Garimella, PhD
At the annual meeting of The Community Oncology Alliance, oncologists sat through a crash course on biosimilars that was rendered by experts from the pharmaceutical industry.
Dr Aimee Tharaldson Expects the Biosimilar Approval Process to Pick Up Speed
June 10th 2016

Dr Aimee Tharaldson Expects the Biosimilar Approval Process to Pick Up Speed

The process for approving biosimilars has been moving slowly, but Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, foresees them as having the potential to lower costs for the industry and hopes the approval process will pick up speed.
Dr Pamela Becker: Bar Is Set Very High to Meet Biosimilar Definition
May 25th 2016

Dr Pamela Becker: Bar Is Set Very High to Meet Biosimilar Definition

The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived differences, according to Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine.
Site Logo
May 5th 2016

Adoption of Biosimilars: Prescriber, Pharmacy and Payer Perspectives

Site Logo
May 3rd 2016

Dr Jeremy Schafer Discusses Paying for Biosimilars and Patient Education

Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value, discussed a number of important topics regarding biosimilars, including how he expects the US will have an easier time approving biosimilars and the importance of patient education about biosimilars.
Site Logo
April 19th 2016

What We're Reading: Theranos Now Subject of a Criminal Investigation

AJMC Staff
What we're reading, April 19, 2016: blood-testing laboratory Theranos is now facing a criminal investigation; biosimilars may not be cheaper than brand name biologics for some seniors; and stigma and misconceptions remain regarding palliative care.
Dr Jeremy Schafer Discusses the Importance of Immunogenicity of Biosimilars
April 19th 2016

Dr Jeremy Schafer Discusses the Importance of Immunogenicity of Biosimilars

The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
Site Logo
April 15th 2016

Industry Insight on the Challenges With Developing and Adopting Biosimilars

Surabhi Dangi-Garimella, PhD
Pharmaceutical industry experts provide an overview of the highly complex biosimilar development process at The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida.
<1
...
1314151617181920>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo